473552-27-1

Basic information

• Product Name: Benzenemethanol, alpha-(aminomethyl)-4-fluoro-, (alphaS)- (9CI)
• Synonyms: Benzenemethanol, alpha-(aminomethyl)-4-fluoro-, (alphaS)- (9CI);Benzenemethanol, a-(aminomethyl)-4-fluoro-, (aS)-;Benzenemethanol, alfa-(aminomethyl)-4-fluoro-, (S)-;a-(aMinoMethyl)-4-fluoro-;(1S)-2-amino-1-(4-fluorophenyl)ethanol
• CAS NO: 473552-27-1
• Molecular Formula: C8H10FNO
• Molecular Weight: 155.1695032
• Product Categories: HALIDE
• Mol File: 473552-27-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzenemethanol, alpha-(aminomethyl)-4-fluoro-, (alphaS)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, alpha-(aminomethyl)-4-fluoro-, (alphaS)- (9CI)(473552-27-1)
• EPA Substance Registry System: Benzenemethanol, alpha-(aminomethyl)-4-fluoro-, (alphaS)- (9CI)(473552-27-1)

Safety Data

• Hazardous Substances Data: 473552-27-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Benzenemethanol, alpha-(aminomethyl)-4-fluoro-, (alphaS)(9CI) is used as a key intermediate in organic synthesis for the development of new compounds and materials. Its unique structure allows for a wide range of chemical reactions, enabling the creation of diverse products with potential applications in various industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Benzenemethanol, alpha-(aminomethyl)-4-fluoro-, (alphaS)(9CI) is utilized as a building block for the synthesis of drug candidates. Its presence in the molecular structure can impart specific biological activities, making it a valuable component in the development of new medications with improved therapeutic properties.
Used in Chemical Processes:
Benzenemethanol, alpha-(aminomethyl)-4-fluoro-, (alphaS)(9CI) is also employed in various chemical processes, such as the production of specialty chemicals, agrochemicals, and other industrial chemicals. Its versatility and reactivity make it a valuable component in the synthesis of a wide range of chemical products.

Upstream product

• 17628-74-9 p-fluorophenylglyoxalmonoxime 
• 133721-87-6 2-(4-fluorophenyl)-2-hydroxyacetonitrile 
• 75-52-5 nitromethane 
• 459-57-4 4-fluorobenzaldehyde 
• 864539-93-5 tert-butyl [2-(4-fluorophenyl)-2-hydroxyethyl]carbamate 
• 456-00-8 2-amino-4'-fluoroacetophenone hydrochloride 
• 1029598-42-2 1-(4-fluorophenyl)-2-nitroethanol 
• 18511-62-1 4-fluorostyrene oxide 
• 403-29-2 2-bromo-4'-fluoroacetophenone 
• 1017172-13-2 2-[2-(4-fluoro-phenyl)-2-hydroxy-ethyl]-isoindole-1,3-dione 
• 82585-50-0 2-[2-(4-fluoro-phenyl)-2-oxo-ethyl]-isoindole-1,3-dione 
• 118887-70-0 2-azido-1-(4-fluoro-phenyl)-ethanone 
• 118888-01-0 rac-2-azido-1-(4-fluorophenyl)ethanol 
• 369-43-7 2-amino-1-(4-fluorophenyl)ethan-1-one 

Downstream Products

• 1426152-48-8 C₁₅H₁₃FN₄O₂S 
• 1426152-52-4 C₁₅H₁₁FN₄O₂S 
• 19338-43-3 5-(4-fluorophenyl)-1,3-oxazolidin-2-one 

Relevant articles and documents

Enantioselective Aminohydroxylation of Styrenyl Olefins Catalyzed by an Engineered Hemoprotein

Chiral 1,2-amino alcohols are widely represented in biologically active compounds from neurotransmitters to antivirals. While many synthetic methods have been developed for accessing amino alcohols, the direct aminohydroxylation of alkenes to unprotected, enantioenriched amino alcohols remains a challenge. Using directed evolution, we have engineered a hemoprotein biocatalyst based on a thermostable cytochrome c that directly transforms alkenes to amino alcohols with high enantioselectivity (up to 2500 TTN and 90 % ee) under anaerobic conditions with O-pivaloylhydroxylamine as an aminating reagent. The reaction is proposed to proceed via a reactive iron-nitrogen species generated in the enzyme active site, enabling tuning of the catalyst's activity and selectivity by protein engineering.

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY

The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use

Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists

A new series of morpholine derivatives has been identified as selective DA D3 receptor antagonists; their in vitro profile and pharmacokinetic data are provided.

One-pot combination of enzyme and Pd nanoparticle catalysis for the synthesis of enantiomerically pure 1,2-amino alcohols

One-pot combinations of sequential catalytic reactions can offer practical and ecological advantages over classical multi-step synthesis schemes. In this context, the integration of enzymatic and chemo-catalytic transformations holds particular potential for efficient and selective reaction sequences that would not be possible using either method alone. Here, we report the one-pot combination of alcohol dehydrogenase-catalysed asymmetric reduction of 2-azido ketones and Pd nanoparticle-catalysed hydrogenation of the resulting azido alcohols, which gives access to both enantiomers of aromatic 1,2-amino alcohols in high yields and excellent optical purity (ee >99%). Furthermore, we demonstrate the incorporation of an upstream azidolysis and a downstream acylation step into the one-pot system, thus establishing a highly integrated synthesis of the antiviral natural product (S)-tembamide in 73% yield (ee >99%) over 4 steps. Avoiding the purification and isolation of intermediates in this synthetic sequence leads to an unprecedentedly low ecological footprint, as quantified by the E-factor and solvent demand.

Efficient preparation of biologically important 1,2-amino alcohols

An efficient three-step methodology developed for the preparation of 1,2-amino alcohols. In the first step a rapid coupling between bromoketones and potassium phthalimide in ionic liquid produced-phthalimido ketones in quantitative yields, which is followed by a facile reduction using NaCNBH 3 in acetic acid to give corresponding phthalimido alcohols and finally effecting hydrazinolysis in water at 60C to yield biologically important 1,2-amino alcohols.

Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors

Protein arginine methyltransferases (PRMTs) play an important role in diverse biological processes. Among the nine known human PRMTs, PRMT3 has been implicated in ribosomal biosynthesis via asymmetric dimethylation of the 40S ribosomal protein S2 and in c

Novel amide- and sulfonamide-based aromatic ethanolamines: Effects of various substituents on the inhibition of acid and neutral ceramidases

In the present study we describe the design and synthesis of a series of amide- and sulfonamide-based compounds as inhibitor of recombinant acid and neutral ceramidases. Inhibition of ceramidases has been shown to induce apoptosis and to increase the efficacy of conventional chemotherapy in several cancer models. B-13, lead in vitro inhibitor of acid ceramidase has been recently shown to be virtually inactive towards lysosomal acid ceramidase in living cells at lower concentrations and for a shorter time of treatment, suggesting the development of more potent inhibitors. In this study, a detailed SAR investigation has been performed to understand the effect of different substituents on the phenyl ring of amide- and sulfonamide-based compounds that partially resemble the structure of well-known inhibitors such as B-13, D-e-MAPP as well as NOE. Our results suggest that the electronic effects of the substituents on phenyl ring in B-13 and D-e-MAPP analogues have negligible effects either in enhancing the inhibition potencies or for selectivity towards aCDase over nCDase. However, the hydrophobicity and the steric effects of longer alkyl chains (n-Pr, n-Bu or t-Bu groups) at the phenyl ring were found to be important for an enhanced selectivity towards aCDase over nCDase.

Regio-selective synthesis of 1,2-aminoalcohols from epoxides and chlorohydrins

A simple and efficient procedure for the regio-selective synthesis of 1,2-aminoalcohols from terminal epoxides and chlorohydrins by using NaHMDS as the source of amine is reported. The wider scope and utility of this method is demonstrated.

ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Indole, indazole and indoline derivatives as CETP inhibitors

The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.